Royal Bank of Canada reissued their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note published on Thursday, Benzinga reports. They currently have a $27.00 price target on the biotechnology company’s stock. Other equities analysts have also recently issued reports about the stock. Oppenheimer restated an outperform rating and set […]

Royal Bank of Canada restated their outperform rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) in a research report released on Thursday morning, Benzinga reports. They currently have a $70.00 target price on the stock. IONS has been the topic of a number of other research reports. Jefferies Financial Group initiated coverage on […]

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a report issued on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright reissued a buy rating and issued a $7.00 target price on shares of Aptose Biosciences in a report on Friday, June […]

Royal Bank of Canada reiterated their outperform rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $77.00 price target on the biopharmaceutical company’s stock. Several other research analysts also recently weighed in on RARE. Stifel Nicolaus upped their price […]

Cantor Fitzgerald restated their overweight rating on shares of Biohaven (NYSE:BHVN – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. Other research analysts also recently issued research reports about the company. HC Wainwright restated a buy rating and issued a $59.00 price objective on shares of Biohaven in a […]

Leerink Partnrs cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a strong-buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. Several other equities research analysts have also recently commented on the company. StockNews.com raised Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a research […]

Biohaven (NYSE:BHVN – Free Report) had its price target upped by Bank of America from $52.00 to $62.00 in a research report report published on Tuesday, Benzinga reports. Bank of America currently has a buy rating on the stock. Several other brokerages also recently weighed in on BHVN. Morgan Stanley assumed coverage on Biohaven in […]

HC Wainwright restated their buy rating on shares of Biohaven (NYSE:BHVN – Free Report) in a research note released on Tuesday morning, Benzinga reports. The firm currently has a $59.00 price objective on the stock. Several other analysts have also weighed in on BHVN. Piper Sandler upped their target price on Biohaven from $66.00 to […]

Foghorn Therapeutics (NASDAQ:FHTX – Free Report) had its target price hoisted by Morgan Stanley from $6.00 to $9.00 in a report published on Tuesday morning, Benzinga reports. The firm currently has an equal weight rating on the stock. Several other research analysts have also recently issued reports on the stock. Evercore ISI began coverage on […]

StockNews.com initiated coverage on shares of HashiCorp (NASDAQ:HCP – Free Report) in a research note published on Tuesday. The brokerage issued a hold rating on the stock. A number of other analysts have also weighed in on HCP. Piper Sandler reaffirmed a neutral rating and issued a $35.00 price objective on shares of HashiCorp in […]

Cantor Fitzgerald restated their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $13.00 target price on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on the company. StockNews.com raised Marinus Pharmaceuticals from a […]

Robert W. Baird initiated coverage on shares of ResMed (NYSE:RMD – Free Report) in a report released on Tuesday morning, MarketBeat.com reports. The firm issued an outperform rating and a $280.00 target price on the medical equipment provider’s stock. A number of other equities analysts have also recently commented on the stock. Wolfe Research reiterated […]

Royal Bank of Canada reaffirmed their outperform rating on shares of IDEAYA Biosciences (NASDAQ:IDYA – Free Report) in a research report report published on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a $61.00 price objective on the stock. Several other equities research analysts have also recently weighed in on the company. Citigroup […]